Summary
Background People with schizophrenia exhibit notable difficulties in the use of everyday language. This directly impacts one’s ability to complete education and secure employment. An impairment in the ability to understand and generate the correct grammatical structures (syntax) has been suggested as a key contributor; but studies have been underpowered, often with conflicting findings. It is also unclear if syntactic deficits are restricted to a subgroup of patients, or generalized across the broad spectrum of patients irrespective of symptom profiles, age, sex, and illness severity.
Methods We conducted a systematic review and meta-analysis, registered on OSF, adhering to PRISMA guidelines, searching multiple databases up to May 1, 2024. We extracted effect sizes (Cohen’s d) and variance differences (log coefficient of variation ratio) across 6 domains: 2 in comprehension (understanding complex syntax, detection of syntactic errors) and 4 in production (global complexity, phrasal/clausal complexity, utterance length, and integrity) in patient-control comparisons. Study quality/bias was assessed using a modified Newcastle–Ottawa Scale. Bayesian meta-analysis was used to estimate domain-specific effects and variance differences. We tested for potential moderators with sufficient data (age, sex, study quality, language spoken) using conventional meta-regression to estimate the sources of heterogeneity between studies.
Findings Overall, 45 studies (n=2960 unique participants, 64·4% English, 79 case-control contrasts, weighted mean age(sd)=32·3(5·6)) were included. Of the patient samples, only 29·2% were women. Bayesian meta-analysis revealed extreme evidence for all syntactic domains to be affected in schizophrenia with a large-sized effect (model-averaged d=0·65 to 1·01, with overall random effects d=0·86, 95% CrI [0·67-1·03]). Syntactic comprehension was the most affected domain. There was notable heterogeneity between studies in global complexity (moderated by the age), production integrity (moderated by study quality), and production length. Robust BMA revealed weak evidence for publication bias. Patients had a small-to-medium-sized excess of inter-individual variability than healthy controls in understanding complex syntax, and in producing long utterances and complex phrases (overall random effects lnCVR=0·21, 95% CrI [0·07-0·36]), hinting at the possible presence of subgroups with diverging syntactic performance.
Interpretation There is robust evidence for the presence of grammatical impairment in comprehension and production in schizophrenia. This knowledge will improve the measurement of communication disturbances in schizophrenia and aid in developing distinct interventions focussed on syntax - a rule-based feature that is potentially amenable to cognitive, educational, and linguistic interventions.
Evidence before this study Prior studies have documented significant language deficits among individuals with psychosis across multiple levels. However, syntactic divergence—those affecting sentence structure and grammar—have not been consistently quantified or systematically reviewed. An initial review of the literature indicated that the specific nature and severity of syntactic divergence, as well as their impact on narrative speech production, symptom burden, and daily functioning, remain poorly defined. We conducted a comprehensive search of the literature up to May 1, 2024, using databases such as PubMed, PsycINFO, Scopus, Google Scholar, and Web of Science. Our search terms combined psychosis, schizophrenia, language production, comprehension, syntax, and grammar, and we identified a scarcity of meta-analytic studies focusing specifically on syntactic comprehension and production divergence in psychosis.
Added value of this study This systematic review and meta-analysis is the first to quantitatively assess syntactic comprehension and production divergence in individuals with psychosis. This study provides estimated effect sizes associated with syntactic impairments as well as a quantification of the variance within patient groups for each domain of impairment. Besides a detailed examination of this under-researched domain, we also identify critical research gaps that need to be addressed to derive benefits for patients from knowledge generated in this domain.
Implications of all the available evidence This study provides robust evidence of grammatical impairments in individuals with schizophrenia, particularly in syntactic comprehension and production. These findings can enhance early detection approaches via speech/text readouts and lead to the development of targeted cognitive, educational, and linguistic interventions. By highlighting the variability in linguistic deficits, the study offers valuable insights for future therapeutic trials. It also supports the creation of personalized formats of information and educational plans aimed at improving the effectiveness of any therapeutic intervention offered to patients with schizophrenia via verbal medium.
Competing Interest Statement
L.P. reports personal fees from Janssen Canada, Otsuka Canada, SPMM Course Limited, UK, Canadian Psychiatric Association; book royalties from Oxford University Press; investigator-initiated educational grants from Sunovion, Janssen Canada, Otsuka Canada outside the submitted work.
Funding Statement
L. Palaniyappan's research is supported by the Canada First Research Excellence Fund, awarded to the Healthy Brains, Healthy Lives initiative at McGill University (through New Investigator Supplement) and Monique H. Bourgeois Chair in Developmental Disorders. He receives a salary award from the Fonds de recherche du Quebec-Sante. This work is supported by the FRQS Partenariat Innovation-Quebec-Janssen (PIQ-J) initiative (#338282); Canadian Institutes of Health Research (CIHR) - Strategy for Patient-Oriented Research Priority Announcement (SPOR; Grant number PJK192157) and Project Grant (Grant number PJT195903); Wellcome Trust Discretionary Grant (226168/Z/22/Z)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
